Methamphetamine Self-Administration Is Associated with Persistent Biochemical Alterations in Striatal and Cortical Dopaminergic Terminals in the Rat by Krasnova, Irina N. et al.
Methamphetamine Self-Administration Is Associated
with Persistent Biochemical Alterations in Striatal and
Cortical Dopaminergic Terminals in the Rat
Irina N. Krasnova
1., Zuzana Justinova
1,2., Bruce Ladenheim
1, Subramaniam Jayanthi
1, Michael T.
McCoy
1, Chanel Barnes
1, John E. Warner
1, Steven R. Goldberg
1, Jean Lud Cadet
1*
1National Institute on Drug Abuse, National Institutes of Health, Baltimore, Maryland, United States of America, 2Department of Psychiatry, University of Maryland School
of Medicine, Baltimore, Maryland, United States of America
Abstract
Methamphetamine (meth) is an illicit psychostimulant that is abused throughout the world. Repeated passive injections of
the drug given in a single day or over a few days cause significant and long-term depletion of dopamine and serotonin in
the mammalian brain. Because meth self-administration may better mimic some aspects of human drug-taking behaviors,
we examined to what extent this pattern of drug treatment might also result in damage to monoaminergic systems in the
brain. Rats were allowed to intravenously self-administer meth (yoked control rats received vehicle) 15 hours per day for 8
days before being euthanized at either 24 hours or at 7 and 14 days after cessation of drug taking. Meth self-administration
by the rats was associated with a progressive escalation of daily drug intake to 14 mg/kg per day. Animals that self-
administered meth exhibited dose-dependent decreases in striatal dopamine levels during the period of observation. In
addition, there were significant reductions in the levels of striatal dopamine transporter and tyrosine hydroxylase proteins.
There were also significant decreases in the levels of dopamine, dopamine transporter, and tyrosine hydroxylase in the
cortex. In contrast, meth self-administration caused only transient decreases in norepinephrine and serotonin levels in the
two brain regions, with these values returning to normal at seven days after cessation of drug taking. Importantly, meth self-
administration was associated with significant dose-dependent increases in glial fibrillary acidic protein in both striatum and
cortex, with these changes being of greater magnitude in the striatum. These results suggest that meth self-administration
by rats is associated with long-term biochemical changes that are reminiscent of those observed in post-mortem brain
tissues of chronic meth abusers.
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Introduction
Methamphetamine (METH) is a highly addictive psychostim-
ulant drug whose abuse has reached epidemic proportions in the
USA and worldwide [1–4]. This presents a serious public concern
because chronic METH abuse is associated with major health
problems including anxiety, depression, psychosis and psychomo-
tor dysfunctions in humans [5,6]. Cognitive studies of chronic
METH users have also found deficits consistent with impaired
functions of striatal and cortical systems. These include deficits in
attention, learning, working memory, and decision making [7–11].
The accumulated evidence is compelling that the negative
neuropsychiatric consequences of METH abuse are related to
drug-induced pathological changes in the brains of METH addicts
[12]. Specifically, clinical imaging studies have demonstrated
significant reductions in the levels of dopamine transporters (DAT)
[8,11,13] and reactive gliosis [14,15] in the brains of METH
abusers. Postmortem analyses of brain tissues obtained from
METH addicts revealed significant decreases in dopamine (DA)
concentrations and in DAT and tyrosine hydroxylase (TH) protein
levels [16–18]. There is also neuroimaging evidence that these
patients suffer from a marked loss of serotonin transporters (5-
HTT) in several brain regions [19], although a recent post-
mortem report showed that the reductions in 5-HTT might not be
as widespread as suggested by the positron emission tomography
data [20].
Animal studies have also provided extensive evidence for
METH-induced damage to dopaminergic and serotoninergic
terminals in rodent and nonhuman primate models using various
drug dosing paradigms [21–23]. These include single large doses
(30–100 mg/kg) or multiple injections of moderate doses (5–
25 mg/kg) of the drug given in one day or over several days to
assess the effects of METH on mammalian monoaminergic
systems [24–28]. Because most rodent experiments involved
multiple METH injections, given in a single day, in order to
assess the effects of METH on brain monoaminergic systems, it
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represent drug-taking behavioral patterns exhibited by METH
addicts [29,30]. For example, acute single-day binge injections do
not replicate the progressive increases in the amount of METH
taken by addicts over time as they develop tolerance to euphoric
and other psychological effects of the drug [29,30]. Because of
these discrepancies, some groups have made attempts to mimic the
human patterns of drug taking by passively increasing the doses of
METH given to rodents [31–35]. Other investigators have used a
METH self-administration paradigm [36–38] and have reported
that animals given extended access to METH escalate their drug
intake [36–38]. These observations have led to the suggestion that
METH self-administration by rodents might represent a better
model of human drug-taking behaviors [36–39]. Two groups of
investigators, who have applied the self-administration approach
using relatively small drug doses with either short (2 hours) [40] or
more prolonged (9 hours) [41] sessions of daily METH exposure,
have failed to find any evidence of significant neurotoxic damages
in monoaminergic terminals in the rat brain. Of related interest,
however, Schwendt at al. [42] have recently reported that
extended (6 hours) access to METH self-administration caused
persistent decreases in DAT protein expression in the prefrontal
cortex and striatum without affecting DA and TH levels in these
brain regions. Because the relative lack of biochemical abnormal-
ities in these reports is not consistent with post-mortem findings in
the brains of human addicts [16–18], more efforts are needed to
clarify the divergent results and to better replicate the neuro-
chemical data observed in the brains of METH addicts. This is of
translational relevance because therapeutic approaches using the
self-administration models need to better approximate the
pathological substrates of METH addicted brains. We reasoned
that larger doses of the drug self-administered over longer periods
of time might be more relevant to human conditions because
METH addicts are known to spend hours injecting METH over
several days [29,30]. Here we present data showing that extended
(15 hours a day) access to METH self-administration over eight
consecutive days which is associated with increasing METH intake
by rats does indeed result in significant decreases of striatal and
cortical DA levels measured up to 14 days after the last drug
session. This pattern of METH administration is also associated
with decreases in the expression of DAT and TH proteins in these
brain regions. Moreover, METH caused increases in the
expression of GFAP, a well-known marker of toxic insults in the
brain [43].
Results
METH Self-Administration and Intake
We used an extended access model of intravenous METH self-
administration to investigate the effects of voluntary METH intake
on monoaminergic systems in the brain. Rats were allowed to self-
administer METH (0.1 mg/kg/injection, i.v.) during daily 15-
hour sessions for 8 consecutive days. Animals in a yoked control
group received injections of saline whenever rats in the test group
self-administered METH. Fig. 1A shows that the average daily
METH intake during each 15-hour daily session in rats gradually
increased starting by the third session (F(7,70)=20.004; p,0.001).
These increases lasted throughout the eighth session, as compared
with the first (p,0.001) and second sessions (p,0.001). Further
escalation of drug taking was manifested by significantly higher
METH intake during the seventh session when compared with the
third session (p,0.05). Self-administration of METH at this level
was maintained during the eighth session. The average daily
intake reached 14.860.8, 14.061.6 and 14.761.1 mg/kg/day for
three groups of animals euthanized at 24 hours, 7 and 14 days,
respectively, after the last METH self-administration session. Total
cumulative drug intake over 8 sessions was 89.167.1, 81.2611.9
and 87.467.2 mg/kg for animals euthanized at 24 hours, 7 and
14 days, respectively, after the last drug session. There were no
significant differences in average daily METH intake or total
amount of drug taken between the groups.
METH-Induced Changes in Body Weight
Fig. 1B shows the effects of METH self-administration on body
weight in rats. There were significant decreases in body weights in
the group of METH-taking rats, with the animals losing about
17% of their weights by the eighth self-administration session. The
yoked saline-receiving group maintained stable weights through-
Figure 1. Changes in METH intake and body weight over the course of self-administration in rats. (A) Escalation of METH intake in rats.
Symbols indicate average daily amount of actively self-administered METH during each of 8 consecutive daily sessions (means 6 SEM; n=11). Rats
increased METH intake on days 3–8 compared with days 1 and 2, and days 7–8 showed further increases in intake compared with day 3. Data
analyzed by one-way ANOVA for repeated measures, followed by Tukey’s multiple comparison test: *** p,0.001 in comparison with sessions 1 and 2,
# p,0.05 in comparison with session 3. (B) METH caused significant decreases in body weight in the animals that actively self-administered the drug
(means 6 SEM; n=9). Data analyzed by two-way ANOVA for repeated measures, followed by Tukey’s multiple comparison test: * p,0.05; *** p,0.001
in comparison to saline group.
doi:10.1371/journal.pone.0008790.g001
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the two groups was significant starting by the fourth session
(F(3,48)=69.62; p,0.001). The observation of weight loss in the
METH group is consistent with the report by Davidson et al. [44]
who also found that rats treated with METH via mini-pumps lost
weight from day 2 onwards during a 7-day drug administration
schedule.
METH-Induced Changes in Monoamine Levels in the Rat
Brain
Striatum. To investigate whether METH self-administration
causes deleterious effects on monoaminergic terminals, we
measured the levels of monoamines in the striatum. METH
induced significant and similar decreases in DA levels in
animals euthanized at 24 hours (239%), at 7 (231%) and at 14
days (228%) after cessation of METH self-administration (F(5,
47)=12.91; p,0.0001) (Fig. 2A). 3,4-dihydroxyindoleacetic acid
(DOPAC) levels were also significantly affected by METH at
24 hours (218%) and 7 days (221%) (F(5,47)=2.49; p=0.044),
while homovanillic acid (HVA) levels were decreased only at the 7-
day time point (224%) (F(5,47)=2.70; p=0.042). In order to assess
if there was a relationship between the dose of METH and striatal
DA depletion, we used regression analysis on the combined
dataset of the three time-points and found a significant negative
correlation between METH intake by individual rats and striatal
DA levels (Pearson’s correlation; r=20.71, r
2=0.50, p,0.0001)
(Fig. 2B). A similar negative correlation (r=20.77, r
2=0.59,
p=0.0003) was also observed when data for only the 14-day time-
point were considered (Fig. 2C).
In addition to the effects on the nigrostriatal dopaminergic
system, METH self-administration was associated with significant
decreases in norephinephrine (NE) (233%) (F(5,47)=4.11;
p=0.004), serotonin (5-HT) (222%) (F(5,47)=7.56; p,0.0001)
and 5-hydroxyindole acetic acid (5-HIAA) (217%) (F(5,47)=3.05;
p=0.018) levels, which were present only at the 24-hour time
point (Fig. 2D). Unexpectedly, the levels of striatal 5-HT were
somewhat higher (+24%) than control values at the 7-day time-
point but were similar to control levels at 14 days after cessation of
METH self-administration.
Cortex. Because binge METH treatment is also known
to affect cortical monoaminergic systems [25,26,45–47], we
examined the effects of METH self-administration in the cortex.
In contrast to the striatal data, METH self-administration was
associated with more gradual decreases in DA levels in the frontal
cortex which reached significance at 14 days post-drug (247%)
(F(5,47)=3.13; p=0.016) (Fig. 3A). DOPAC concentrations were
not affected (Fig. 3A). Similar to the observations in the striatum,
cortical DA levels correlated negatively with the doses of METH
Figure 2. Effects of METH self-administration on monoamine levels in the striatum. METH caused persistent decreases in striatal DA levels
(A), which negatively correlated with total drug intake when data at 24 hours, 7 and 14 days after cessation of self-administration were combined (B)
and at 14 days post-drug (C). However, only transient changes were found in the levels of NE and 5-HT (D). Data shown as mean 6 SEM. *, p,0.05; **,
p,0.01; ***, p,0.001 vs control. Data were analyzed by ANOVA followed by PLSD, n=7211 per group. Correlation analysis was done by regression
analysis.
doi:10.1371/journal.pone.0008790.g002
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points (r=20.33; r
2=0.11; p=0.0146) (Fig. 3B). Similar results
were obtained for the 14-day time-point (r=20.53; r
2=0.28;
p=0.0233) (Fig. 3C).
Animals that self-administered METH exhibited decreases in
NE levels in the frontal cortex at 24 hours (224%) (F(5,47)=3.89;
p=0.005) after cessation of drug intake but not at other times
(Fig. 3D). There were also METH-induced decreases in 5-HT
levels only at the 24-hour time-point (224%) (F(5,47)=2.45,
p=0.047) but no significant changes in 5-HIAA levels (Fig. 3D).
Effects of METH Self-Administration on TH, DAT, and 5-
HTT Protein Levels in the Striatum and Cortex
Because the accumulated evidence has suggested that toxic
doses of METH can cause damage to monoaminergic terminals in
the rodent brain [23], we used Western blot analysis to measure
levels of TH, DAT and 5-HTT, markers of DA and 5-HT
terminal integrity, in the striata and cortices of animals euthanized
at 14-day time-point. Fig. 4A shows the results of Western blots in
the striatum while Fig. 4B presents the quantitative data obtained
from these experiments. METH self-administration caused
significant decreases in striatal TH (239%) (F(1,16)=12.84;
p=0.003) and DAT (237%) (F(1,16)=14.24; p=0.002) protein
levels. However, there were no significant changes in the
expression of 5-HTT protein (Fig. 4B). Similar to the striatum,
METH self-administration induced significant decreases in the
levels of cortical TH (245%) (F(1,16)=6.41; p=0.022) and DAT
(223%) (F(1,16)=5.11, p=0.040) without affecting 5-HTT protein
expression (Fig. 5A and B).
Effects of METH Self-Administration on GFAP Levels in
the Striatum and Cortex
Toxic doses of METH are also known to cause reactive
astrocytosis in the mammalian brain [48,49]. Therefore, we used
Western blot analysis to measure levels of GFAP in the striata
and cortices of animals euthanized at the 7-day time-point. The
results of the Western blots in the striatum are shown in Fig.
6A and the quantitative data are presented in Fig. 6B. METH
self-administration caused marked increases in striatal GFAP
levels (+370%) (F(1,12)=23.131; p=0.0004), which correlated
positively with the doses of METH self-administered by the
animals (r=0.94; r
2=0.88; p,0.0001) (Fig. 6C). There were
also significant METH-induced increases in GFAP levels in the
cortex (+58%) (F(1,12)=15.042; p=0.0019) (Fig. 6D and E).
Similar to the striatal observations, there was a positive
correlation between GFAP expression in the cortex and total
METH intake by individual animals (r=0.74; r
2=0.55; p=0.003)
(Fig. 6F).
Figure 3. Effects of METH self-administration on monoamine levels in the cortex. METH self-administration resulted in long-term
reductions in DA concentrations in the cortex (A). DA levels showed negative correlations with total METH intake at the 24 hour, 7 and 14 days time-
points (B) and at 14 days after cessation of self-administration (C). METH caused only transient reductions in NE and 5-HT concentrations in the cortex
(D). Data shown as mean 6 SEM. *, p,0.05; **, p,0.01 vs control. Data were analyzed by ANOVA followed by PLSD, n=7211 per group. Correlation
analysis was done by regression analysis.
doi:10.1371/journal.pone.0008790.g003
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The present experiments demonstrated that (1) extended access
to METH self-administration was associated with a progressive
escalation of drug intake by rats and significant decreases in their
body weights; (2) this pattern of METH intake resulted in
persistent dose-dependent depletion of striatal and cortical DA
levels measured at various times after cessation of drug treatment;
(3) METH self-administration also caused decreases in the
expression of striatal and cortical TH and DAT proteins; and (4)
METH induced dose-dependent increases in GFAP expression in
both, striatum and cortex.
Our results are in agreement with findings from post-mortem
studies that have reported decreased DA levels and reduced TH
and DAT protein expression in the striata of human METH
addicts [16–18]. They are also consistent with animal studies
showing that METH treatment can cause persistent abnormalities
in the markers of DA system integrity in various brain regions
[25–27,45,50]. Our findings are also in agreement with clinical
data demonstrating reactive astrocytosis in the brains of chronic
METH abusers [14] and with observations of reactive astrocytosis
in rodent striatum following METH injections [48,49,51].
However, our results are different from those of Shepard et al.
[41] and Stefanski et al. [40] who reported that METH self-
administration did not induce persistent changes in markers of DA
system integrity in the rat brain. Yet, they are in partial agreement
with data of Schwendt et al. [42], who showed very recently that
METH self-administration caused decreases in the expression of
DAT protein in the striatum and cortex without affecting DA
concentrations or TH protein levels. Possible reasons for the
differences include the use of lower doses of self-administered
METH and the shorter daily drug access allowed to rats in these
studies. Specifically, Stefanski et al. [40] reported that rats self-
administered 2.5 mg/kg/day of METH over a 2-hour daily
session, Schwendt et al. [42] stated that rats self-administered
about 7 mg/kg/day during 6-hour sessions, while Shepard et al.
[41] found that their animals took 7.9 mg/kg/day of METH
during 9 hours of access. In the present study, rats reached an
average METH intake of 14 mg/kg/day during the 15-hour
sessions. Together, these findings suggest that METH can cause
both neuroadaptative and neurotoxic changes in the mammalian
brain depending on the intake, with lower doses of METH being
able to induce transient alterations in markers of DA system
integrity [40,41] or neuroadaptive decreases in DAT protein
expression without affecting DA and TH levels in the brain [42].
In contrast, higher METH doses can cause persistent abnormal-
ities in DA, DAT, and TH levels that can last weeks and months
after cessation of drug administration [25,35,45,50]. The idea that
METH causes dose-dependent alterations in the brain is
supported by the present observations of negative correlation
Figure 4. METH self-administration causes reductions in DAT and TH protein levels in the striatum. (A) Representative immunoblots
show expression of TH, DAT and 5-HTT protein levels in the striatum 14 days after last METH self-administration session. (B) Quantitative analyses of
immunoblots reveal significant decreases in TH and DAT, but no change in 5-HTT expression in the METH-treated rats. Data presented as mean 6
SEM. ** p,0.01 vs control. Data were analyzed by ANOVA followed by PLSD, n=7211 per group.
doi:10.1371/journal.pone.0008790.g004
Figure 5. METH self-administration resulted in decreased expression of DAT and TH proteins in the cortex. (A) Immunoblots showing
TH, DAT and 5-HTT protein expression in the cortex 14 days after cessation of METH intake. (B) Quantification of METH toxic effects demonstrates
significant decreases in TH and DAT, but not in 5-HTT protein levels. Data shown as mean 6 SEM. * p,0.05; ** p,0.01 vs control. Data were analyzed
by ANOVA followed by PLSD, n=7211 per group.
doi:10.1371/journal.pone.0008790.g005
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METH self-administered by individual rats. This discussion is
further supported by the reports of positive correlation between
METH intake and cell death in the prefrontal cortex [37] but
negative correlation between METH intake and hippocampal
volume [39] in rodents.
The mechanisms underlying METH-induced neurotoxic
effects are thought to involve the production of reactive oxygen
(ROS) and reactive nitrogen species (RNS) which overwhelm
antioxidant defense systems in the brain [21,23]. ROS and RNS
can damage macromolecules such as DNA, proteins, and lipids
causing oxidative stress [52]. Although neurons are thought to be
very susceptible to oxidative injury [53,54], oxidative stress can
also trigger cellular and molecular responses that lead to
activation of glia-mediated events which might cause additional
damage to the brain [55–57]. Similar mechanisms appear to
participate in the degeneration of the nigrostriatal DA pathway
that occurs in Parkinsonism [57,58]. Thus, the present observa-
tions showing greater magnitude of METH-induced reactive
astrocytosis in the striatum than in the cortex might be
responsible, in part, for the more severe abnormalities observed
in that brain region. This might occur through the production of
proinflammatory cytokines and chemokines by reactive glia
[56,58]. It is, nevertheless, possible that trophic factors secreted
by astrocytes [59,60] might also play role in the delayed partial
recovery that occurs in the brain of rodents treated with toxic
doses of METH [23,25,45].
Extending the duration of daily self-administration sessions to
15 hours resulted in an escalating increase in METH intake
similar to reported in previous studies that used extended access to
the drug [36–38,42]. Because METH intake was also reported to
escalate in human abusers during development of METH
dependence [29,30], the present model appears to better replicate
some aspects of the human condition. The quantity of METH
intake (about 14 mg/kg/day) reached by rats in our study is within
the range of doses used by some human abusers who inject
comparatively large doses of METH (11.7–32 mg/kg/day) during
runs and binges [29,30]. An important consequence of the large
METH doses administered by these rats was the loss of body
weight. This physiological complication is consistent with
significant anorexia and weight loss reported by human abusers
[30,61,62]. In fact, amphetamines have been used and abused in
the self-treatment of obesity [62–64].
The METH-induced weight losses observed in the present study
are consistent with the results reported by Bittner et al. [65] who
found decreases in body weight in rats treated with a high-dose
METH regimen (50 mg/kg given twice a day for 4 days). These
METH doses also caused striatal DA depletion [65]. Moreover,
Davidson et al. [44] also showed that treatment of rats with 7-day
METH by minipumps (20 mg/kg/day) caused weight loss from
day 2 onwards after implantation of the pumps. Although our
results are in contrast to the report of Shepard et al. [41] who
found that rats which self-administered lower doses of METH did
not lose weight, the accumulated evidence suggests that METH
Figure 6. Effects of METH self-administration on GFAP expression in the striatum and cortex. Representative Western blot analyses show
that the METH self-administering rats had increased GFAP levels in their striata (A) and cortices (D). Quantitative analyses of the Western blots show
significant increases in GFAP levels in the METH-treated rats (B, E). Key to statistics: ** p,0.01, *** p,0.001 (ANOVA, n=7 per group). GFAP expression
showed significant positive correlation with METH intake in the striatum (C) and cortex (F).
doi:10.1371/journal.pone.0008790.g006
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interest that Barsdley and Bachelard [66] reported that rats treated
chronically with METH experienced decreases in TH enzyme
activity in their brains only if they continued to experience the
anorectic effects of the drug. Tolerant animals did not show any
METH-induced biochemical deficits [66]. Therefore, when taken
together with findings of significant weight loss in the present
study, all these observations suggest that resistance to METH-
induced anorexia during self-administration might predict, to a
certain degree, tolerance to neurotoxic effects of METH.
In summary, this is the first demonstration that the striatal and
cortical dopaminergic systems of rats can sustain damage from
METH self-administration when animals are given extended
access to higher doses of the drug, in a manner comparable to
experienced human addicts who are known to abuse large
quantities of intravenous METH during runs and binges
[29,30]. Because of the similarities between our results and those
of human post-mortem studies that have recorded substantial
depletion of DA levels and decreases in the expression of TH
and DAT proteins in the brains of METH addicts [16–18], it is
possible to suggest that rodent models aimed at replicating these
biochemical deficits should allow for longer periods of daily
access to the drug during self-administration experiments. Finally,
because the present model also replicates patterns of METH
abuse by humans, it might serve to better inform translational
developments of therapeutic approaches to METH addiction.
Materials and Methods
METH Self-Administration
Subjects. Male Sprague-Dawley rats (Charles River,
Wilmington, MA), weighing approximately 350–420 g at the
beginning of the self-administration experiment, were individually
housed in a temperature- and humidity-controlled environment
under a reversed lighting 12-h light/dark cycle (lights on at 7:00
p.m.). The rats were allowed free access to food (NIH07 biscuits) in
their home cage throughout the study. Water was available ad
libitum in the home cage and in the testing chamber. Rats were
tested in the light phase. They were experimentally and drug naı ¨ve
at the beginning of this study.
Animals were maintained in facilities fully accredited by the
American Association for the Accreditation of Laboratory Animals
and all experiments were conducted in accordance with the
guidelines of the Institutional Care and Use Committee of the
Intramural Research Program, NIDA, NIH, and the Guidelines
for the Care and Use of Mammals in Neuroscience and Behavioral
Research (National Research Council 2003).
Apparatus. Eighteen standard operant-conditioning cham-
bers (Coulbourn Instruments, Lehigh Valley, PA) were used. Each
chamber contained a white house light and two holes with nose-
poke operanda on either side of a food trough. Each nose poke
produced a brief feedback tone. One hole was defined as active
(left in nine chambers, right in remaining nine) and the other hole
as inactive. METH or saline were delivered through Tygon
tubing, protected by a metal spring and suspended through the
ceiling of the experimental chamber from a single-channel fluid
swivel. The tubing was attached to a syringe pump (Harvard
Apparatus, South Natick, MA), which was programmed to deliver
2-s injections. The injected volume was adjusted for every animal
to deliver a METH dose of 0.1 mg/kg/injection. Experimental
events were controlled by microcomputers using MED Associates
interfaces and software (Med Associates Inc., East Fairfield, VT).
Under anesthesia with a mixture of ketamine and xylazine (60
and 10 mg/kg i.p., respectively), rats were prepared with a silastic
catheter implanted into the external jugular vein, with the catheter
exiting the skin behind the ear. After catheter implantation, a
nylon bolt glued to an acrylic mesh was implanted subcutaneously
in the midscapular region. The nylon bolt served as a tether,
preventing the catheter from being pulled out during self-
administration sessions. Following surgery, the IV catheter was
flushed daily during the first week with 0.2–0.3 ml of sterile 0.9%
saline containing heparin (1.25 units/ml) and gentamicin (10 mg/
ml) and then flushed after each daily session with heparin solution
to maintain its patency.
Procedure. Each of the three experimental groups started
with 18 naı ¨ve rats that were divided into two groups and tested
simultaneously. One group served as yoked controls and passively
received an injection of saline (which was not contingent on
responding) each time a response-contingent injection of 0.1 mg/
kg METH was actively self-administered by the first group of rats.
Nose-poke responses by the yoked control rats were recorded, but
had no programmed consequences. The first two experimental
groups consisted of 9 rats self-administering METH and 9 yoked
control rats. The third experimental group consisted of 11 rats self-
administering METH and 7 yoked control rats.
15-hour sessions were conducted for 8 consecutive days,
between 5 p.m. and 9 a.m. At the beginning of each session, a
white house light was turned on and a priming injection of
0.1 mg/kg METH (or saline for yoked group), sufficient to fill the
‘‘dead’’ space of the IV catheter, was automatically delivered.
Each nose-poke response in the active hole (fixed-ratio one, FR1)
delivered an IV injection of 0.1 mg/kg of METH followed by 30-s
timeout period, during which the chamber was dark and responses
in either hole had no programmed consequences. Nose-poke
responses in the ‘‘inactive’’ hole were recorded but had no
programmed consequences. After eight sessions, rats were
euthanized by decapitation. The first group of rats was euthanized
at 24 hours, the second group at 7 days and the third group at 14
days after the last session ended. Brains were quickly removed and
dissected on an iced plate.
HPLC
For monoamine analysis, striata and cortices dissected from rat
brains were homogenized in 0.01 M HClO4 and centrifuged at
18,0006g for 15 min. NE, DA, DOPAC, HVA, 5-HT and 5-
HIAA levels were analyzed in brain tissue extracts using HPLC
with electrochemical detector as previously described [67].
Monoamine levels were expressed as ng/mg of tissue weight and
reported as % of control concentrations for ease of presentation.
Western Blot
Western blot analyses were carried out as previously published
[68]. In brief, striatal and cortical samples were washed with ice-
cold 0.1 M PBS, homogenized in lysis buffer (0.01 M Tris-HCl,
pH 7.6, 0.1 M NaCl, 0.001 M EDTA, 100 mg/ml PMSF and
1 mg/ml aprotinin) and then centrifuged at 15,0006g for 30 min.
Protein concentration were determined with BioRad Dc Protein
assay (BioRad, Temecula, CA). 10 mg of protein (striatum)
and 40 mg of protein (cortex) were electrophoresed on 10%
SDS-polyacrylamide gels and then transferred to Hybond-P
TM
membrane (GE Healthcare, Piscataway, NJ). The membranes
were blocked and then immunolabeled with antibodies against
DAT (1:1000), TH (1:4000), 5-HTT (1:1000) and GFAP (1:5000)
(all from Millipore, Billerica, MA) at 4uC overnight. Immune
complexes were detected with HRP-labeled second antibody and
ECL+ chemiluminescence reagents (GE Healthcare). To confirm
equal protein loading, blots were stripped and reprobed with a-
tubulin antibody (1:2000; Sigma, St. Louis, MO) for 2 hours at
Meth Intake and DA Terminals
PLoS ONE | www.plosone.org 7 January 2010 | Volume 5 | Issue 1 | e8790room temperature. Signal intensity was measured using densito-
metric analysis (UVP Inc., Upland, CA) and quantified using
LabWorks analysis software (version 4.5).
Statistical Analyses
All data are presented as means 6 SEM. Statistical analysis of
self-administration experimental data was performed using one-
way analysis of variance (ANOVA) for repeated measures (intake)
or two-way ANOVA for repeated measures (weights) followed by a
pairwise multiple comparison procedure (Tukey’s test) to identify
differences between the sessions or groups, respectively (SigmaStat
software: http://www.systat.com.) Statistical analysis of biochem-
ical data was performed using ANOVA followed by Fisher’s
protected least significant difference (PLSD) (StatView 4.02, SAS
Institute, Cary, NC). The relationship between METH intake, DA
levels and GFAP expression was determined using Pearson’s
regression analysis (Origin 6.1, Origin Lab, Northampton, MA).
The null hypothesis was rejected at p,0.05.
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